OakChart

Ginkgo Bioworks Holdings Inc

DNAHealthcare·Biotechnology·USA·Small·NYSE·Nov 11 • 8:40 AM ET

12.50+0.49 (4.08%)
2026-11-11 14:40 CET
Market cap
772.73 USD m
Revenue, TTM
100.74 USD m
Net income, TTM
-275.54 USD m
Free cash flow, TTM
-173.54 USD m
EPS diluted, TTM
-4.63
P/E
-
Compare

Price

DNA against its 20, 50 and 200-day averages
2050200beatearnings
10.0015.006.6M13.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DNAclose 12.5020-day 11.0350-day 10.22200-day 8.6512.50

31.4% under 18.22 on 6 Oct 2026. Last 15 sessions, 50.5% high to low

Profile

DNA
52-week range, 55% of the way up
5.3718.22

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

IndexRUT
Employees485
IPOApr 19, 2021
Beta1.72
ATR, 14d1.37
Rel volume0.05
Short float19.32%
Insider own23.67%
Inst own60.29%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap828.22M
Enterprise Value938.20M
Income-275.54M
Sales100.74M
Book/sh6.38
Cash/sh4.33
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees485
IPOApr 19, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S8.22
P/B1.96
P/C2.88
P/FCF-
EV/EBITDA-
EV/Sales9.31
Quick Ratio4.72
Current Ratio4.72
Debt/Eq1.01
LT Debt/Eq1.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.63
EPS next Y-4.03
EPS next Q-1.04
EPS this Y22.78%
EPS next Y7.58%
EPS next 5Y16.87%
EPS past 3/5Y51.73% -7.49%
Sales past 3/5Y-29.11% 17.29%
EPS Y/Y TTM25.63%
Sales Y/Y TTM-44.22%
EPS Q/Q55.86%
Sales Q/Q-28.65%
EarningsNov 05 AMC
EPS/Sales Surpr.5.59% 28.89%

Ownership

Insider Own23.67%
Insider Trans-0.86%
Inst Own60.29%
Inst Trans8.45%
ROA-23.91%
ROE-53.57%
ROIC-34.89%
Gross Margin40.40%
Oper. Margin-242.27%
Profit Margin-273.52%
SMA2013.32%
SMA5022.35%
SMA20044.58%
Trades-

Technical

Shs Outstand53.62M
Shs Float49.11M
Short Float19.32%
Short Ratio4.03
Short Interest9.49M
52W High18.22 -31.39%
52W Low5.37 132.77%
Volatility14.53% 12.06%
ATR (14)1.37
RSI (14)56.34
Beta1.72
Rel Volume0.05
Avg Volume2.36M
Volume6,443

Performance

Perf Week7.30%
Perf Month6.29%
Perf Quarter72.65%
Perf Half Y45.52%
Perf YTD50.42%
Perf Year47.75%
Perf 3Y-75.59%
Perf 5Y-97.68%
Perf 10Y-
Recom4.33
Target Price8.00
Prev Close12.01
Price12.50
Change %4.08%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Aug 07, 2026DowngradeTTD CowenBuy → Hold$9-28.0%
May 15, 2024DowngradeBBTIG ResearchNeutral → Sell
May 10, 2024DowngradeWWilliam BlairMkt Perform → Underperform
Nov 14, 2023DowngradeRRaymond JamesOutperform → Mkt Perform$3.50 → $2.50-80.0%
Nov 09, 2023DowngradeBBTIG ResearchBuy → Neutral
Jun 02, 2023DowngradeGGoldmanNeutral → Sell$3 → $1.25-90.0%
May 11, 2023DowngradeWWilliam BlairOutperform → Mkt Perform
Nov 29, 2022InitiatedBBerenbergBuy$6-52.0%
Oct 04, 2022InitiatedMMorgan StanleyEqual-Weight$5-60.0%
May 18, 2022DowngradeBBofA SecuritiesNeutral → Underperform$3-76.0%

Peers

Mkt cap
TickerCompanyMkt cap
ABSIAbsci Corp1.79B
TWSTTwist Bioscience Corp9.22B
RXRXRecursion Pharmaceuticals Inc2.32B
ABCLAbCellera Biologics Inc4.15B
GENBGenerate Biomedicines Inc1.66B
CDXSCodexis Inc111.70M
MRVIMaravai LifeSciences Holdings Inc2.14B
NAUTNautilus Biotechnology Inc301.87M
SEERSeer Inc83.61M
DYAIDyadic International Inc, DE14.90M

Insider trading

latest 14 of 56
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Coen Steven P.See remarksOct 19 '26Sale10.147667,77050,168Oct 21 04:07 PM
Canton Barry10% OwnerOct 19 '26Sale10.1422,369226,889453,951Oct 21 04:06 PM
Canton Barry10% OwnerOct 19 '26Sale10.1418,803190,719356,329Oct 21 04:06 PM
Shetty Reshma P.See remarksOct 19 '26Sale10.1422,369226,889453,951Oct 21 04:06 PM
Shetty Reshma P.See remarksOct 19 '26Sale10.1418,803190,719356,329Oct 21 04:06 PM
Kelly Jason RSee remarksOct 19 '26Sale10.1445,682463,353129,065Oct 21 04:05 PM
Coen Steven P.OfficerOct 19 '26Proposed Sale10.147667,769Oct 19 03:58 PM
Canton BarryOfficerOct 19 '26Proposed Sale10.1418,803190,711Oct 19 03:47 PM
Che AustinOfficerOct 19 '26Proposed Sale10.1416,058162,870Oct 19 03:45 PM
Shetty Reshma P.OfficerOct 19 '26Proposed Sale10.1422,369226,880Oct 19 03:42 PM
Kelly Jason ROfficerOct 19 '26Proposed Sale10.1445,682463,334Oct 19 03:38 PM
Che AustinOfficerOct 19 '26Proposed Sale10.382,20022,836Oct 19 10:08 AM
Coen Steven P.See remarksOct 05 '26Sale15.002,40336,04549,448Oct 07 05:00 PM
Coen Steven P.OfficerOct 05 '26Proposed Sale15.002,40336,045Oct 05 02:04 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
IWMiShares Russell 2000 Index FundAUM: 78.30B
VXFVanguard Extended Market Index ETFAUM: 30.61B
IWNiShares Russell 2000 Value ETFAUM: 14.17B
THNQROBO Global Artificial Intelligence ETFAUM: 411.03M
IBBiShares Biotechnology ETFAUM: 11.47B
KOMPState Street SPDR S&P Kensho New Economies Composite ETFAUM: 2.49B
VTWOVanguard Russell 2000 Index ETFAUM: 16.97B
SCHASchwab U.S. Small-Cap ETFAUM: 22.32B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.57B

News

latest 14 of 204
  • Ginkgo Bioworks Misses On EPS, But A Revenue Beat, Narrowing Losses And A Novo Lab Sale Advance Its Autonomous-Lab Pivot (Earnings Whispers) -14.51% +13.35%
  • Ginkgo Bioworks Must Show Revenue Has Bottomed As Loss Expected To Narrow Sharply (Earnings Whispers) -12.01%
  • Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program (Business Wire) +14.64%
  • Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop (PR Newswire)
  • What Needs To Be True To Buy Twist Bioscience Stock Now? (Trefis)
  • Loading…
  • Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data (Business Wire)
  • Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines (Business Wire)
  • Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery (PR Newswire)
  • The $59B Quiet Shift Reshaping How Patients Access Care (PR Newswire)
  • Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab (PR Newswire) -13.47%
  • Earnings To Watch: Ginkgo Bioworks Holdings Inc (DNA) Reports Q1 2026 Result (GuruFocus.com)
  • Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation (PR Newswire) +12.80%
  • Elon Musk Endorses 'Fundable' Jurassic Park: These De-Extinction Companies Are Already Making It Happen (Benzinga)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.640-0.678-0.64027.7121.502
2026Q22026-08-05-0.750-0.895-1.14720.1624.052
2026Q12026-05-07-1.390-1.211-1.38719.4742.932
2025Q42026-02-26-1.410-1.455-1.45633.0037.092
2025Q32025-11-06-1.450-1.241-1.45238.8438.953
2025Q22025-08-07-1.100-1.567-1.09949.6041.603
2025Q12025-05-06-1.680-1.534-1.67748.3238.805
2024Q42025-02-25-2.000-1.504-1.99843.8544.475
2024Q32024-11-12-1.080-2.728-1.08089.0544.994
2024Q22024-08-08-4.400-3.098-4.23156.2143.145
2024Q12024-05-09-3.200-3.332-3.31137.9445.976
2023Q42024-02-29-4.400-3.868-4.28234.7642.506
2023Q32023-11-08-6.400-3.656-6.21055.4348.087
2023Q22023-08-09-3.600-3.452-3.58680.5771.508
2023Q12023-05-10-4.400-3.400-4.29080.7071.738
2022Q42023-03-01-4.000-8.324-3.80798.2988.647

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-55.600-7.900-46.883313.84251.52
2022FY-50.000-55.632-50.145477.71471.16
2023FY-18.400-17.600-18.368251.46258.72
2024FY-10.540-10.080-10.541227.04227.75
2025FY-5.640-5.640-5.680170.16173.86
2026FY--4.355--87.47
2027FY--4.025--95.73
2028FY--3.240--92.60
2029FY--2.240--369.1

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0631024.1022.1027.30
2026Q4S2026-10-2630023.8322.1027.30
2026Q4S2026-10-2030123.8322.1027.30
2026Q4S2026-10-0130223.8322.1027.30
2026Q4S2026-09-0330323.8322.1027.30
2026Q4S2026-08-1220222.1022.1022.10
2026Q4S2026-08-0620125.7522.1029.40
2026Q4S2026-07-2220130.1529.4030.90
2026Q4S2026-07-1420230.1529.4030.90
2026Q4S2026-06-1920232.3529.4035.30
2026Q4S2026-05-0830233.6029.4036.09
2026Q4S2026-03-1430237.4336.0938.20
2026Q4S2026-03-1130337.4336.0938.20
2026Q4S2026-03-1030337.4336.0938.20

Estimate history

EPS, annual-3.93-46.883-50.145-18.368-10.541-5.64-4.6302
Period202020212022202320242025TTM
EPS, quarterly-1.08-1.998-1.677-1.099-1.452-1.456-1.387-1.147-0.641
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual76.657313.837477.706251.455227.043170.155100.74
Period202020212022202320242025TTM
Sales, quarterly89.04643.84748.31849.60438.83733.39619.47420.15627.711
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual32.21540.28542.29947.03351.36655.20761.497
Period202020212022202320242025MRQ
Shares, quarterly50.08251.36651.69852.42553.83655.20758.66160.71161.497
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue100.74170.16227.04251.46477.71313.8476.66
Cost of Goods Sold Incl. D&A60.0487.2689.57108.81265.85144.5929.48
Gross Profit40.7082.89137.47142.64211.86169.2547.18
Selling, General and Administrative Excl. Other284.76397.00597.77814.872,373.781,997.11184.21
Research and Development141.09203.48359.25525.811,052.641,134.76159.77
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-244.06-314.11-460.30-672.23-2,161.92-1,827.87-137.03
Interest Expense--0.090.090.112.372.38
Unusual Expense5.509.18114.61187.01-77.94-79.34-8.79
Net Income Before Taxes-255.98-313.60-547.51-892.94-2,121.40-1,838.12-124.83
Income Taxes-0.87-0.84-0.48-0.07-15.03-1.481.89
Consolidated Net Income-255.12-312.76-547.03-892.87-2,106.37-1,836.64-126.72
Net Income From Continuing Operations-255.12-312.76-547.03-892.87-2,104.93-1,830.05-126.61
Net Income-275.54-312.76-547.03-892.87-2,104.93-1,830.05-126.61
EPS (Recurring)-4.25-5.52-9.00-15.67-51.52-48.26-4.12
EPS (Basic, Before Extraordinaries)-4.63-5.64-10.54-18.37-50.15-45.43-3.93
EPS (Diluted)-4.63-5.64-10.54-18.37-50.15-46.88-3.93
EBITDA-193.25-255.12-397.28-600.68-2,100.29-1,798.79-123.16
Non-Operating Income (Expense)-6.429.6927.50-33.61-37.31-87.225.79
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense41.1964.4288.75185.581,533.331,228.270.35
Price To Sales Ratio8.152.712.2413.075.9442.67-
Gross Margin40.4048.7260.5556.7344.3553.9361.55
Operating Margin-242.27-184.60-202.74-267.34-452.56-582.43-178.75
Net Margin-273.52-183.81-240.94-355.08-440.63-583.12-165.16
Shares Outstanding61.5055.2151.3747.0342.3040.2832.21
Market Capitalization772.73772.73534.983,131.112,447.5613,390.6713,335.81

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue27.7120.1619.4733.4038.8449.6048.3243.85
Cost of Goods Sold Incl. D&A13.8414.0315.9016.2626.9730.6127.4120.57
Gross Profit13.876.123.5817.1311.8718.9920.9123.27
Selling, General and Administrative Excl. Other57.5563.5674.9588.70100.0887.40106.82124.90
Research and Development28.9133.9037.1241.1655.1937.5855.5665.42
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-43.68-57.44-71.37-71.57-88.22-68.41-85.92-101.63
Interest Expense-------0.00
Unusual Expense1.18-0.881.213.99-4.20-2.641.468.53
Net Income Before Taxes-41.26-57.19-76.14-81.39-80.75-60.58-90.87-107.86
Income Taxes-0.270.13-0.08-0.640.00-0.280.09-0.33
Consolidated Net Income-40.98-57.32-76.06-80.75-80.75-60.30-90.96-107.53
Net Income From Continuing Operations-40.98-57.32-76.06-80.75-80.75-60.30-90.96-107.53
Net Income-40.98-71.22-82.59-80.75-80.75-60.30-90.96-107.53
EPS (Recurring)-0.63-1.16-1.37-1.41-1.50-1.13-1.66-1.88
EPS (Basic, Before Extraordinaries)-0.64-1.15-1.39-1.46-1.45-1.10-1.68-2.00
EPS (Diluted)-0.64-1.15-1.39-1.46-1.45-1.10-1.68-2.00
EBITDA-31.64-45.13-58.58-57.90-74.05-52.62-70.55-85.97
Non-Operating Income (Expense)3.60-0.63-3.55-5.843.275.19-3.492.29
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.066.0012.5216.6114.0917.5816.1416.24
Price To Sales Ratio8.155.502.582.714.492.671.302.33
Gross Margin50.0430.3718.3751.3030.5638.2843.2753.08
Operating Margin-157.62-284.99-366.51-214.30-227.14-137.92-177.81-231.77
Net Margin-147.90-353.33-424.09-241.80-207.93-121.56-188.25-245.25
Shares Outstanding61.5060.7158.6655.2153.8452.4351.7051.37
Market Capitalization772.73617.63357.74478.57819.39624.73313.69534.98

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments429.65567.41948.861,324.011,550.00380.80
Short Term Receivables24.2522.4431.7484.03149.9024.93
Inventories0.000.000.054.363.362.74
Other Current Assets17.9312.8921.1037.6819.7818.07
Total Current Assets471.84602.741,001.751,450.081,723.05426.54
Net Property, Plant & Equipment528.70598.15397.22718.79145.77121.44
Total Investments and Advances53.2087.04119.29159.30115.23103.12
Long-Term Note Receivable7.1314.1713.6037.660.0013.30
Intangible Assets56.9272.51131.98171.2542.955.15
Other Assets1.902.831.502.2443.995.60
Total Assets1,119.701,377.451,665.342,539.322,070.99675.15
Short Term Debt Incl. Current Port. of LT Debt22.8128.9619.9329.330.750.48
Accounts Payable10.5714.179.3210.458.1913.89
Other Current Liabilities62.6064.13134.60133.18125.8358.84
Total Current Liabilities95.97107.27163.86172.96134.7673.22
Long Term Debt417.08438.77221.84413.2622.2816.52
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities98.06115.36182.50216.83346.57115.36
Total Liabilities611.11661.39568.19803.04503.61205.10
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity508.59716.061,097.151,736.281,505.37461.38
Total Shareholders Equity508.59716.061,097.151,736.281,505.37461.38
Accumulated Minority Interest0.000.000.000.0062.018.68
Total Equity508.59716.061,097.151,736.281,567.38470.05
Total Liabilities & Stockholders Equity1,119.701,377.451,665.342,539.322,070.99675.15
Book Value Per Share9.2113.9423.3341.0537.3714.32
Tangible Book Value Per Share8.1812.5320.5237.0036.3014.16
Full-Time Employees4858341,2181,2926412
Price to Book Ratio1.880.622.501.718.908.60
Return on Assets-25.05-35.96-42.47-91.31-176.62-
Return on Equity-51.08-60.34-63.02-129.87-243.13-
Return on Invested Capital-33.79-47.37-67.69-97.92-119.80-26.49
Quick Ratio4.925.626.118.3612.765.79
Current Ratio4.925.626.118.3812.795.83

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-255.12-312.76-547.03-892.87-2,103.49-1,836.64-126.72
Depreciation50.8158.9963.0271.5561.6329.0813.86
Other Funds (Non Cash)104.53128.17255.03496.781,841.271,615.293.54
Funds from Operations-101.13-126.97-229.91-325.34-215.19-192.28-109.31
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-65.86-44.09-89.6729.84-37.01-61.54-26.52
Cash from Operating Activities-166.99-171.06-319.58-295.50-252.20-253.82-135.83
Capital Expenditures-6.56-7.67-62.54-40.80-52.27-56.52-57.82
Net Assets From Acquisitions-0.000.00-42.98-63.36-12.040.00
Sale of Fixed Assets and Businesses-0.57-4.754.4382.3759.930.00
Purchase or Sale of Investments111.15-233.254.520.00-3.69-5.000.00
Purchase of Investments-233.59-418.630.000.00-3.69-5.000.00
Sale Or Maturity of Investments344.74185.384.520.000.000.000.00
Other Uses0.000.000.00-1.34-40.440.00-10.10
Other Sources0.050.050.540.0010.000.300.80
Cash from Investing Activities105.22-240.29-62.24-80.69-67.39-13.32-67.12
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock31.1618.130.08-0.4998.081,484.8091.07
Repurchase of Common Pref Stock0.000.000.000.000.00-25.000.00
Sale of Common Pref Stock31.1618.130.08-0.4998.081,509.8091.07
Proceedsfrom Stock Options31.1618.13-0.00-0.5897.841,509.6391.04
Issuance or Reduction of Debt, Net-0.04-0.35-0.90-1.29-1.24-1.12-0.75
Change in Long Term Debt-0.04-0.35-0.90-1.29-1.24-1.12-0.75
Issuance of Long Term Debt0.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.04-0.35-0.90-1.29-1.24-1.12-0.75
Net Financing Active Other Cash Flow0.000.00-0.92-1.43-1.50-9.460.00
Other Financing Activities Uses0.000.00-0.92-1.43-1.50-9.460.00
Cash from Financing Activities31.1217.77-1.74-3.2295.341,474.2190.32
Exchange Rate Effect-0.230.20-0.28-0.590.91-0.020.00
Net Change in Cash-30.88-393.37-383.84-380.00-223.351,207.05-112.63
Free Cash Flow-173.54-178.72-382.13-336.30-304.47-310.34-193.65
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit--1.36-0.94-0.80-14.610.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments287.22305.08380.34429.65470.67484.64
Short Term Receivables11.4813.0120.2724.2522.3623.13
Inventories0.000.000.000.000.000.00
Other Current Assets12.1314.449.3517.9313.0615.26
Total Current Assets310.84332.54409.95471.84506.08523.02
Net Property, Plant & Equipment493.84504.85516.82528.70544.79562.15
Total Investments and Advances98.79106.9552.6253.2067.2769.50
Intangible Assets39.7344.3948.8656.9261.5266.15
Other Assets1.251.324.811.902.382.64
Total Assets944.45990.051,033.081,119.701,189.161,231.01
Short Term Debt Incl. Current Port. of LT Debt0.000.000.0022.810.000.00
Accounts Payable7.189.5716.3110.5710.7011.20
Other Current Liabilities58.6763.1663.2962.60104.5885.52
Total Current Liabilities65.8572.7479.5995.97115.2896.72
Long Term Debt397.20404.11410.70417.08422.87428.83
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities88.7792.9199.6398.0691.2392.51
Total Liabilities551.82569.76589.92611.11629.38618.06
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity392.64420.28443.15508.59559.78612.95
Total Shareholders Equity392.64420.28443.15508.59559.78612.95
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity392.64420.28443.15508.59559.78612.95
Total Liabilities & Stockholders Equity944.45990.051,033.081,119.701,189.161,231.01
Book Value Per Share6.386.927.559.2110.4011.69
Tangible Book Value Per Share5.746.196.728.189.2610.43
Full-Time Employees---485--
Price to Book Ratio1.881.310.670.801.250.90
Return on Assets-23.91-26.55-25.61-25.05-25.43-22.07
Return on Equity-53.57-57.08-54.63-51.08-50.02-43.59
Return on Invested Capital-5.19-8.64-9.67-8.72-8.22-5.79
Quick Ratio4.724.575.154.924.395.41
Current Ratio4.724.575.154.924.395.41

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-40.98-57.32-76.06-80.75-80.75-60.30
Depreciation12.0412.3112.8013.6614.1715.79
Other Funds (Non Cash)15.5413.8830.7544.3621.2026.97
Funds from Operations-13.40-31.13-32.51-24.09-45.38-17.54
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-14.94-13.15-14.18-23.5913.78-22.71
Cash from Operating Activities-28.35-44.27-46.69-47.68-31.61-40.25
Capital Expenditures-2.00-2.62-1.93-0.010.00-0.04
Net Assets From Acquisitions0.00--0.000.000.00
Sale of Fixed Assets and Businesses0.00--0.570.000.00
Purchase or Sale of Investments-22.5713.7125.0294.99-73.06-63.99
Purchase of Investments-89.36-44.28-83.16-16.79-81.71-128.95
Sale Or Maturity of Investments66.7957.99108.18111.788.6464.96
Other Uses0.000.000.000.000.000.00
Other Sources0.460.000.05-0.460.250.14
Cash from Investing Activities-24.1011.0923.1395.10-72.82-63.89
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock6.5016.490.008.179.960.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock6.5016.490.008.179.960.00
Proceedsfrom Stock Options6.5016.490.008.179.960.00
Issuance or Reduction of Debt, Net0.000.00-0.02-0.03-0.02-0.10
Change in Long Term Debt0.000.00-0.02-0.03-0.02-0.10
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.00-0.02-0.03-0.02-0.10
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities6.5016.49-0.028.149.94-0.10
Exchange Rate Effect0.010.04-0.13-0.150.090.19
Net Change in Cash-45.94-16.65-23.7055.41-94.39-104.05
Free Cash Flow-30.35-46.89-48.62-47.68-31.61-40.29

Revenue breakdown

United States2024: 227.04M 2025: 170.16M
Biosecurity2024: 53.07M 2025: 37.41M
Cell Engineering2024: 173.97M 2025: 132.75M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3019.32%9.5M49.1M2.20M
2026-10-1516.89%8.3M49.1M1.92M
2026-09-3014.90%7.3M49.1M1.36M
2026-09-1514.60%7.2M49.1M1.11M
2026-08-3114.06%6.9M48.8M1.19M
2026-08-1411.46%5.6M48.8M1.14M
2026-07-3110.89%5.3M48.8M1.20M
2026-07-1511.07%5.2M47.0M1.26M
2026-06-3010.97%5.2M47.0M1.25M
2026-06-1510.43%4.9M47.0M1.24M
2026-05-299.79%4.6M46.6M1.22M
2026-05-159.72%4.5M46.6M1.24M
2026-04-3012.01%5.2M43.6M1.21M
2026-04-1513.99%6.1M43.6M1.17M
2026-03-3114.03%6.1M43.8M1.15M
2026-03-1318.27%8.0M43.8M1.11M
2026-02-2717.08%7.5M43.8M1.04M
2026-02-1317.05%7.3M42.6M1.03M
2026-01-3015.73%6.7M42.6M1.03M
2026-01-1516.51%7.0M42.6M1.10M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.0010.6011.809.2021.9325.000.000.994-0.0140.000
call2.009.6010.808.1212.6024.000.000.986-0.0240.001
call3.008.609.8011.989.4500.000.000.981-0.0250.001
call4.007.608.805.477.5540.000.000.975-0.0250.001
call5.006.607.800.006.2000.000.000.969-0.0240.001
call6.005.607.004.005.68214.000.000.961-0.0240.002
call7.004.605.806.454.2699.000.000.952-0.0230.002
call8.003.704.304.502.3561840.000.940-0.0220.002
call9.002.753.803.652.84558.000.000.923-0.0200.003
call10.001.902.702.552.0632460.000.820-0.0380.005
call11.001.201.952.101.8401,0230.000.696-0.0480.007
call12.000.751.050.851.3246161.000.545-0.0510.008
call13.000.250.800.451.50461916.000.422-0.0590.008
call14.000.100.650.501.6836310.000.340-0.0620.007
call15.000.050.550.191.2578441060.166-0.0320.005
call16.000.000.200.201.4861560.000.147-0.0340.005
call17.000.000.400.151.6911,5020.000.134-0.0370.004
call18.000.000.350.051.8775200.000.124-0.0390.004
call19.000.000.150.101.90856.000.000.096-0.0330.003
call20.000.000.600.102.0602590.000.091-0.0340.003
call21.000.000.600.202.20042.000.000.086-0.0350.003
call22.000.000.600.102.33277.000.000.083-0.0360.003
call23.000.000.600.202.4561140.000.080-0.0370.003
call24.000.000.250.102.57251.000.000.077-0.0370.003
call25.000.000.600.002.6830.000.000.075-0.0380.003
call26.000.000.600.002.7880.000.000.073-0.0390.003
call27.000.000.600.002.8870.000.000.071-0.0390.003
call28.000.000.600.002.9820.000.000.069-0.0400.003
call29.000.000.600.003.0720.000.000.068-0.0400.003
call30.000.000.100.112.9381.000.000.049-0.0300.002
put1.000.000.050.007.8970.000.00-0.006-0.0130.000
put2.000.000.600.006.6450.000.00-0.014-0.0240.001
put3.000.000.600.005.1530.000.00-0.019-0.0240.001
put4.000.000.600.004.1390.000.00-0.025-0.0240.001
put5.000.000.600.003.3700.000.00-0.031-0.0240.001
put6.000.000.600.002.7470.000.00-0.039-0.0230.002
put7.000.000.450.102.21820.000.00-0.048-0.0220.002
put8.000.000.100.281.75727.000.00-0.060-0.0210.002
put9.000.050.100.401.3401181.00-0.077-0.0190.003
put10.000.050.300.201.399387125-0.180-0.0360.005
put11.000.150.550.451.30187.001.00-0.304-0.0470.007
put12.000.750.950.851.226264100-0.455-0.0500.008
put13.001.201.701.051.40557.000.00-0.578-0.0580.008
put14.001.852.602.601.64825.000.00-0.660-0.0610.007
put15.002.803.503.001.8136.000.00-0.834-0.0300.005
put16.003.704.405.801.9162.000.00-0.853-0.0330.005
put17.004.505.402.952.1461.000.00-0.866-0.0350.004
put18.005.506.400.002.3540.000.00-0.876-0.0370.004
put19.006.607.400.002.5450.000.00-0.904-0.0310.003
put20.007.608.407.602.7210.000.00-0.909-0.0320.003
put21.008.609.400.002.8840.000.00-0.914-0.0330.003
put22.009.6010.409.703.0360.000.00-0.917-0.0330.003
put23.0010.6011.400.003.1790.000.00-0.920-0.0340.003
put24.0011.6012.400.003.3130.000.00-0.923-0.0350.003
put25.0012.6013.400.003.4410.000.00-0.925-0.0350.003
put26.0013.6014.400.003.5610.000.00-0.927-0.0360.003
put27.0014.6015.400.003.6760.000.00-0.929-0.0360.003
put28.0015.6016.400.003.7850.000.00-0.931-0.0370.003
put29.0016.6017.400.003.8900.000.00-0.932-0.0370.003
put30.0017.6018.400.003.9890.000.00-0.951-0.0270.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-19144Filing for proposed sale of securities under Rule 144.SEC
2026-10-19144Filing for proposed sale of securities under Rule 144.SEC
2026-10-19144Filing for proposed sale of securities under Rule 144.SEC
2026-10-19144Filing for proposed sale of securities under Rule 144.SEC
2026-10-19144Filing for proposed sale of securities under Rule 144.SEC
2026-10-19144Filing for proposed sale of securities under Rule 144.SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-30SCHEDULE 13G/ASEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-17144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10001.34M7
2026-090035.41K1
2026-08002.30K1
2026-07005.94K1
2026-060000
2026-05002.56K1
2026-04003.54M10
2026-03004.77K1
2026-020000
2026-01008.67K1
2025-12006.54K1
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.6.87%
VIKING GLOBAL INVESTORS LP5.74%
Erste Asset Management GmbH4.07%
BAILLIE GIFFORD & CO3.72%
VANGUARD CAPITAL MANAGEMENT LLC3.35%
Anchorage Capital Group, L.L.C.2.80%
Legal & General Group Plc2.68%
STATE STREET CORP2.36%
GEODE CAPITAL MANAGEMENT, LLC1.99%
FORBES J M & CO LLP1.52%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.39%
iShares Russell 2000 ETF2.01%
VANGUARD EXTENDED MARKET INDEX FUND0.88%
Fidelity Small Cap Index Fund0.84%
PIMCO RAE US Small Fund0.81%
iShares Russell 2000 Value ETF0.72%
iShares Biotechnology ETF0.57%
ROBO Global Artificial Intelligence ETF0.57%
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF0.52%
VANGUARD RUSSELL 2000 INDEX FUND0.42%

OakChart. DNA. Cached 15 minutes.